Aesthetic Surgery Journal · Nov 19, 2026

Occult Malignancy and Atypical Proliferative Lesions in Reduction Mammaplasty Specimens Without History of Breast Cancer: Systematic Review and Meta-Analysis

By Skorochod R, Gronovich Y

ABSTRACT: Reduction mammaplasty specimens are routinely submitted for histopathological examination, although the clinical value of this practice remains debated because of the low prevalence of occult malignancy and widespread use of preoperative breast imaging. The authors performed a systematic review and meta-analysis according to PRISMA 2020 and MOOSE guidelines to determine the prevalence of occult malignancy and atypical proliferative lesions in reduction mammaplasty specimens from patients without a personal history of breast cancer. PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched from inception through March 1, 2026. Twenty-eight studies comprising 74,847 patients were included. The pooled prevalence was 0.25% (95% CI, 0.19%-0.34%) for invasive carcinoma, 0.28% (95% CI, 0.19%-0.43%) for ductal carcinoma in situ, 0.33% (95% CI, 0.18%-0.61%) for lobular carcinoma in situ, 1.39% (95% CI, 1.09%-1.78%) for atypical ductal hyperplasia, 1.30% (95% CI, 0.80%-2.10%) for atypical lobular hyperplasia, and 0.31% (95% CI, 0.13%-0.73%) for flat epithelial atypia. Clinically relevant occult lesions continued to be identified among patients who proceeded to reduction mammaplasty following comprehensive preoperative imaging. Histopathological examination therefore retains residual diagnostic yield following preoperative evaluation and provides complementary information for identifying clinically significant occult breast pathology.

doi.org/10.1093/asj/sjag254PubMed 43055120Biomarkers

AgingResearch.News